Skip to main content

Live Viridian Therapeutics, Inc. Common Stock Share Price Chart

O 30.17H 30.17L 30.17

Viridian Therapeutics, Inc. Common Stock Performance Overview

Days Range
▼
$30.17Low
$31.37High

Markets Today

Previous Close$30.12
Open$30.17
Volume2,118,373
Day's Range$30.17 - $31.37
52W RangeNA
Market Cap$3.41 B

Historical Performance

1M Returns+44.81
3M Returns+21.45
6M Returns+88.60
1Y Returns+5.02
5Y Returns+54.86
10Y ReturnsNA

Viridian Therapeutics, Inc. Common Stock Fundamentals

Market Cap$3.41 B
Dividend yieldN/A
PE RatioN/A
PEG RatioN/A
Revenue$70.85 M
ROE TTMN/A
EPS TTMN/A
Quarterly Earnings Growth YOYN/A
PB RatioN/A
EBITDA$-362.94 M
Profit Margin-397.93
Market Cap$3.41 B
Dividend yieldN/A
PE RatioN/A
PEG RatioN/A
Revenue$70.85 M
ROE TTMN/A
EPS TTMN/A
Quarterly Earnings Growth YOYN/A
PB RatioN/A
EBITDA$-362.94 M
Profit Margin-397.93

Viridian Therapeutics, Inc. Common Stock Profit & Loss

Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Total Revenue +$75.00 K$70.57 M$132.00 K$141.00 K$284.00 K$25.75 M
Gross Profit +$75.00 K$70.57 M$132.00 K$141.00 K$284.00 K$24.23 M
Operating Income -$106.77 M-$40.01 M-$122.75 M-$116.84 M-$126.27 M-$103.48 M
EBITDA -$106.65 M-$39.90 M-$122.63 M-$116.72 M-$126.15 M-$103.13 M
Interest Expense -$514.00 K-$560.00 K-$3.28 M-$3.46 M-$8.31 M-$9.27 M
Depreciation $113.00 K$110.00 K$120.00 K$121.00 K$117.00 K$343.00 K
Income Before Tax -$100.73 M-$34.60 M-$120.36 M-$104.90 M-$127.12 M-$101.21 M
Income Tax Expense $0$0$0$0$0$0
Net Income +-$100.73 M-$34.60 M-$120.36 M-$104.90 M-$127.12 M-$101.21 M
Net Profit Margin -134313.33%-49.03%-91178.03%-74397.87%-44760.21%-393.01%

Viridian Therapeutics, Inc. Common Stock Financials Balance Sheet In USD

Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Share Capital $817.00 K$822.00 K$1.02 M$1.02 M$1.13 M$1.14 M
Reserve & Surplus -$1.18 B-$1.22 B-$1.34 B-$1.44 B-$1.57 B-$1.67 B
Non-Current Liabilities $14.57 M$23.47 M$106.56 M$101.20 M$371.34 M$377.92 M
Current Liabilities $52.59 M$50.70 M$70.70 M$51.80 M$63.79 M$70.05 M
Total Liabilities $67.16 M$74.17 M$177.25 M$153.01 M$435.14 M$447.97 M
Fixed Assets $1.09 M$1.13 M$1.23 M$1.13 M$12.77 M$12.76 M
Current Assets $578.75 M$571.91 M$894.23 M$784.74 M$1.08 B$1.01 B
Total Assets $582.32 M$577.14 M$899.42 M$789.02 M$1.10 B$1.03 B

Viridian Therapeutics, Inc. Common Stock Cash Flow

Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Net Income -$100.73 M-$34.60 M-$120.36 M-$104.90 M-$127.12 M-$101.21 M
Operating Cash Flow -$75.37 M-$84.61 M-$23.75 M-$119.65 M-$105.32 M-$92.77 M
Investing Cash Flow $75.72 M$126.08 M-$339.42 M$77.26 M-$231.16 M$24.34 M
Financing Cash Flow $764.00 K$10.86 M$405.91 M$6.36 M$325.12 M$77.61 M
Change in Cash $1.11 M$52.32 M$42.73 M-$36.04 M-$11.36 M$9.17 M

Viridian Therapeutics, Inc. Common Stock Return Calculator

The Viridian Therapeutics, Inc. Common Stock stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Returns Estimator

Based on past performance of this fund

ENTER AMOUNT
$10,000
Select Duration
5Yrs
1 Yr5 Yrs
If you had invested $10,000 5 years ago, what would its value be today?$15,928
Invested Amount$10,000
Est. Returns$5,928
Invest in USA Stock Today

About Viridian Therapeutics, Inc. Common Stock

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

FAQs

Viridian Therapeutics, Inc. Common Stock (VRDN) share price as of November 20, 2026 is $30.98. If you are investing from India, you can always check the valuation in the INR before investing.
Yes, Indian Investors can invest in the Viridian Therapeutics, Inc. Common Stock (VRDN) Share by opening an international trading account with Angel One.
Purchasing Viridian Therapeutics, Inc. Common Stock (VRDN) share from India can be done by: Directly: By opening an international trading account with Angel One. The process would include KYC verification. The account activation takes a few minutes to a few hours, after which you can start buying Viridian Therapeutics, Inc. Common Stock (VRDN) by making deposits in US dollars. Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.
Yes, you can purchase fractional shares of Viridian Therapeutics, Inc. Common Stock (VRDN) or any other US company shares in Angel One for any dollar amount.
The market capitalization of Viridian Therapeutics, Inc. Common Stock on November 20, 2026, is $3.41 B.
Viridian Therapeutics, Inc. Common Stock operates in the Healthcare sector, specifically in the Healthcare industry.
In order to invest in Viridian Therapeutics, Inc. Common Stock (VRDN) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.). From start to end, the process is digital and can be seamless.